Tag: Motley Fool

The SportsHero Ltd (ASX: SHO) share price fell heavily today despite announcing a positive update in regards to the company’s latest performance. At the closing bell, SportsHero shares finished the day down 14.2% to 5.4 cents.

Let’s take a closer look at why its shares fell today and what was released.

What’s driving the SportsHero share price down?

While the SportsHero share price fell 14% today, a major catalyst for this was that investors were selling their shares for a profit. Just yesterday, the company’s shares skyrocketed from 3.9 cents at market open to close at 6.3 cents. This represents a gain of around 61% in just 6 hours of trade.

Although the company’s shares fell today, not all was bad. According to its release, SportsHero advised it has reached a significant milestone in achieving 3,043,955 new unique users from its OlahBola app.

Launched on 7 July 2020, the OlahBola app is an Indonesian locally branded and localised international football app. The platform allows fans to watch and follow football such as the English Premier League and Spain’s La Liga.

SportsHero noted that the sharp increase in users is due to its attractive offering which has been increasing in awareness. Since the company’s last report in February, 342,483 new users have been added to its customer base. This has led SportsHero to grow its sales pipeline.

It estimates that the total addressable market is around 100 million users, giving plenty of room to grow in future.

Quick take 

Established in 2016, SportsHero is a gamified social sports prediction platform where users can predict, interact, and compete on all major sports. The social competition platform ranks fans in which top performers received prize giveaways such as merchandise, event tickets, and in-app virtual currency.

CEO commentary

SportsHero CEO, Tom Lapping, touched on the company’s performance. He said:

The total Indonesian addressable market is around 100 million. We have now surpassed 3 million new unique users, well ahead of schedule and growing at a compound rate of 31% month on month.

The SportsHero share price has gained more than 125% since this time last year.

More reading

• Why did the BPH Energy (ASX:BPH) share price tank 24% today?
• Here’s why the Resonance Health (ASX:RHT) share price rocketed
• Why did Aussie investors get a 9% dividend cut from CSL (ASX:CSL)?
• The Coles (ASX:COL) share price is down 10% in two days: Time to buy?
• Palla Pharma (ASX:PAL) share price rockets 30% higher. Here’s why

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What happened to the SportsHero (ASX:SHO) share price today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2OPdPob

The BPH Energy Ltd (ASX: BPH) share price continues to do its dance of speculation. Up and down, the volatility persists, as it has since late January. The culprit appears to be the contest over whether a drilling program will go ahead.

Shares closed the day at 16.5 cents, down 24%.

Why is the BPH Energy share price falling?

The story so far

On 1 February BPH Energy announced its proposal to use the Sydney Basin drilling program to investigate the potential for a carbon capture and storage (CCS) project. The company proceeded to conduct a capital raise to fund the proposed project.

However, the party was crashed when NSW Deputy Premier John Barilaro stated he would refuse applications to extend the PEP11 oil project. This put BPH in a precarious position after already raising capital. The issue is PEP11 encompasses the area where BPH would deploy its CCS project.

BPH Energy clarified to shareholders that the project was subject to both state and federal government approval. Additionally, in the situation where federal and state levels are not in agreeance, the federal decision wins out.

Due to the erratic price and volume movements, BPH Energy received an ASX Price/Volume Query yesterday. Today’s announcement addresses the queries made by the ASX.

Price query response

The company outlined its recent updates to the market that may have had an influence on the share price. Furthermore, the company noted there have been several media statements by the Joint Authority members, which includes the Federal Government Minister for Resources and the respective NSW Minister.

BPH Energy highlighted comments made by the Federal Minister Senator Hon. Keith Pitt MP on 12 February 2021, who stated that “A decision on Petroleum Exploration Permit 11 off the New South Wales coast” would not be delivered on that day and also indicated his “preference for the decision on the permit extension to be made soon.”

In addition, Senator Pitt noted that detailed consideration would be given to the approval. This comment suggests there is potential the project may still be turned down. 

The BPH Energy share price dropped by as much as 30% in intraday trade in response and closed the day down 24% at 16.5 cents.

More reading

• Why BPH Energy (ASX:BPH) shares are now in a trading halt
• Why the BPH Energy (ASX:BPH) share price is crashing 21% lower today
• Why the BPH Energy (ASX:BPH) share price rocketed 32% higher today
• BHP Energy and Zip were among the most traded ASX shares last week
• Why BPH Energy (ASX:BPH) shares are in a trading halt

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why did the BPH Energy (ASX:BPH) share price tank 24% today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3s9a4IB

The Resonance Health Ltd (ASX: RHT) share price rocketed more than 16% today before closing 5% higher.

The booming share price moves come after the company emerged from a trading halt late this morning. This follows the release of an announcement on its medical device.

What did Resonance Health report to send its shares higher?

In a late morning ASX release, Resonance Health announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its HepaFat-AI device. The device provides fully automated artificial intelligence software to assesses liver fat.

With the TGA approval, Resonance Health can now supply its device across Australia. The company had already received clearance from the United States Food & Drug Administration (FDA) in early December.

HepaFat-AI automatically analyses magnetic resonance imaging (MRI) data. Subsequently, this data assesses liver fat in patients to give physicians a new tool in assessing patients with confirmed or suspected fatty liver disease.

According to Resonance Health, doctors can use the device to monitor patients for a number of issues. This will include patients in weight loss programs and screening the livers of live donors for transplant suitability. Additionally, the device will monitor patients who have or are believed to have non-alcoholic fatty liver disease (NAFLD) or the more serious subtype, non-alcoholic steatohepatitis (NASH).

Resonance Health reports that “NAFLD affects up to 2.3 billion people, a figure expected to grow year-on-year. Of these, about 470 million people (or 20%) will develop NASH”. NASH can lead to serious health consequences, including liver failure.

The company plans to market the device to radiologists and physicians involved in the routine clinical diagnosis and management of patients with confirmed or suspected fatty liver disease. However, it also sees a market with pharmaceutical companies engaged in NASH drug development.

Resonance Health says its work in machine learning to develop assistance tools for the medical sector is continuing.

Share price snapshot

Over the past 12 months, Resonance Health shares are up 2.5%. That compares to a 1% loss on the All Ordinaries Index (ASX: XAO).

Year-to-date, the Resonance Health share price is down 10.8%.

More reading

• Resonance Health (ASX:RHT) announces its share price is in trading halt

Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Resonance Health (ASX:RHT) share price rocketed appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Zt3LDq

CSL Limited (ASX: CSL) announced its FY21 half-year result to the market today. In the result was a 9% dividend cut for Aussie investors.

Why did CSL cut the dividend for Aussies?

To understand what happened, it’s important to note that CSL reports its result in US dollars. It also makes a lot of its revenue and profit in US currency too.

So, bearing that in mind, some investors may have been surprised to see that in Australian dollar currency terms, the interim dividend that CSL declared represented a 9% cut to approximately $1.34 per share.

However, in US dollar terms, the interim dividend was actually increased by the CSL board by 9% to US$1.09 per share. A year ago the Australian dollar with worth around US$0.67 and now it’s worth around US$0.78.

What was the rest of the CSL result like?

CSL reported that it delivered a strong first half result with reported net profit after tax (NPAT) growth of 44% to US$1.8 billion. Earnings per share (EPS) also grew by 44% to US$3.98.

The large healthcare business said that there was solid growth of its core immunoglobulin portfolio. It also said there was a successful transition to its own distribution model in China, this helped albumin sales grow by 93%. This new distribution model is expected to help improve CSL’s participation in the value chain as well as improving its sales, marketing and distribution network.

CSL also said that there was exceptionally strong growth by the vaccine division, Seqirus. This was achieved by growth in seasonal influenza vaccines, driven by record demand and the ongoing shift to Seqirus’ differentiated product portfolio.

New manufacturing facility

During the six month period, CSL announced that it would be building a new biotech manufacturing facility in Australia to manufacture influenza vaccines for countries around the world.

This facility will use cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs. It will be the only cell-based influenza vaccine facility in the southern hemisphere.

Expectations for the rest of the year

CSL CEO and managing director Paul Perreault said:

Demand for CSL’s core plasma, and influenza vaccine products remains robust. Seqirus is performing well as strong demand for influenza vaccines together with our differentiated products portfolio will see it deliver another strong profitable year. Consistent with the seasonal nature of the business we anticipate, however, a loss in the second half of the year.

CSL’s net profit after tax for FY21 is anticipated to be in the range of approximately US$2.17 billion to US$2.265 billion at constant currency, representing growth over FY20 of up to 8%.

More reading

• ASX 200 up 0.2%: ANZ and CSL impress, Fortescue declares huge interim dividend
• Why CSL, Domino’s, IPH, & Treasury Wine shares are storming higher
• CSL (ASX:CSL) share price pops on increased dividend
• CSL (ASX:CSL) share price on watch after 45% jump in half year profit
• 5 things to watch on the ASX 200 on Thursday

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why did Aussie investors get a 9% dividend cut from CSL (ASX:CSL)? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3u4fuXb

The Coles Group Ltd (ASX: COL) share price was out of form again on Thursday and tumbled lower.

The supermarket giant’s shares finished the day 5.5% lower at $16.23.

This means the Coles share price is now down 10.5% over the last two trading sessions.

Why is the Coles share price tumbling lower?

The catalyst for this decline has been the release of Coles’ half year results on Wednesday.

Although the company delivered a strong result, concerns over market share losses and a tough near term outlook have been weighing on the Coles share price.

In case you missed it, Coles reported an 8% increase in revenue to $20,569 million and a 14.5% increase in net profit to $560 million for the six months ended 31 December. This was driven by solid growth across all segments.

While this outperformed the market’s expectations, this wasn’t due to its Supermarket segment.

According to a note out of Goldman Sachs, it was forecasting an 8.7% jump in Supermarket sales to $18,022.6 million. However, Supermarket sales only rose 7.6% to $17,800 million.

The broker commented: “Coles delivered a 1H21 result modestly ahead of expectations with sales +8.1% to A$20.4bn and EBIT +12.1% to A$1.02bn, 2% ahead of GSe although the outperformance came from the lower value non-food divisions.”

Based on this growth rate, it appears to believe Coles is losing supermarket market share to rivals Metcash Limited (ASX: MTS) and Woolworths Group Ltd (ASX: WOW).

What else was weighing on the Coles share price?

The other catalyst for the weakness in the Coles share price was management’s comments in relation to the second half.

It warned: “Depending on COVID-19, vaccine roll out and efficacy, and other factors, sales in the supermarket sector may moderate significantly or even decline in the second half of FY21 and into FY22. Coles will be cycling elevated sales from COVID-19 in Supermarkets late in the third quarter, for the remainder of the second half, and most of FY22.”

Is this a buying opportunity?

Despite the above, Goldman Sachs remains very positive on the company. As such, it has retained its buy rating but trimmed its price target slightly to $20.70.

This price target implies potential upside of 27.5% over the next 12 months. This increases to over 31% if you include its 3.8% fully franked dividend yield.

Goldman commented: “While it will likely be difficult to grow top line sales growth in this environment, we expect profits to be modestly easier to maintain given elevated costs in the base and COL’s ongoing cost out program, “Smarter Selling” which is on track to deliver A$250mn in cost out this year.”

“We have made only modest revisions to group EBIT +0.8% and +1.1% in FY21 and FY22, as improved earnings in Liquor and convenience offset a 1-1.5% decline in our Food EBIT forecasts. We revise our Price Target -1.9% to A$20.70, implying a 24.2% [then] forecast total return. Maintain Buy.”

More reading

• Why Bellevue Gold, Coles, NRW, & Perpetual shares are trading lower today
• Why the Coles (ASX:COL) share price is sinking 6% today
• Why Coles, Netwealth, Pro Medicus, & Zip shares are sinking
• ASX 200 down 0.5%: Domino’s delivers, Westpac impresses, Coles sinks
• Coles (ASX:COL) share price on watch following half year update

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The Coles (ASX:COL) share price is down 10% in two days: Time to buy? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3dorH2M

The Palla Pharma Ltd (ASX: PAL) share price is among the top performers on the ASX market today. This comes after the company announced that it had received approval to change its manufacturing site to its Norway production facility.

During late afternoon trade, shares in the opiate-based pain relief medicine company are up 30.3% to 73 cents. It’s worth noting that the company’s shares rose to an intraday high of 82 cents in the first hour of market open.

Production facility change

The Palla Pharma share price is on the move after reporting a significant tailwind in its operations.

In today’s release, Palla Pharma advised that United Kingdom’s medicines regulator, MHRA, has given the green light to change the manufacturing site for its Co-Codamol tablet.

Palla Pharma’s Co-Codamol products contain two painkilling ingredients, paracetamol and codeine. The tablet form product relieves short-lasting painful conditions where paracetamol alone is insufficient.

In addition to the approval, the regulator also gave the nod for the company’s required marketing authorisations, as well as patient information leaflets and product packaging.

As a result, Palla Pharma immediately began producing its initial batches of the product in bulk. Once it has completed the packing process, it will move onto its sales process. The company noted that production would ramp up to meet the anticipated demand for the coming months.

The UK is the biggest market in Europe for painkiller relief tablets. Each kilogram of codeine phosphate sold as part of the approved Co-Codamol product has a higher gross margin than in active pharmaceutical ingredient form or tableted form as a contract manufacturer. This in-turn represents an increase in revenue generation for the company.

Palla Pharma revealed that it would release its full-year results on Friday, 26 February.

About the Palla Pharma share price

The Palla Pharma share price has taken investors on a rollercoaster ride in the past 12 months. The company’s shares dipped to an all-time low of 45 cents in March, before storming to a 52-week high of $1.08.

At today’s current share price of 72 cents, Palla Pharma is down around 15% from this time last year.

More reading

• Abacus Property (ASX:ABP) just revealed 85% profit growth in HY21
• Top brokers name 3 ASX shares to sell today
• What’s going on with the MyFiziq (ASX:MYQ) share price today?
• Here’s why the Mach7 (ASX:M7T) share price is down 6% today
• Why the EML Payments (ASX:EML) share price is still pushing higher

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Palla Pharma (ASX:PAL) share price rockets 30% higher. Here’s why appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Zr5kS7

Abacus Property Group (ASX: ABP) has reported a significant increase in statutory profit in its FY21 half-year result.

Abacus is a property business that owns two large property portfolios – one is office and the other is self-storage.

Why did Abacus Property’s profit soar?

The property group announced that its statutory profit went up 85% to $151.8 million. The business disclosed that the revaluation process of its property portfolio resulted in a net increase in the investment property values for the first half of FY21 of $93.9 million.

There was a gain of $97.5 million, or 8.4%, across the self-storage portfolio. However, the office portfolio suffered a $3.6 million decline, or 0.2%, across the commercial portfolio.

In terms of the operating rental profit, the funds from operations (FFO) fell 9.9% to $60.6 million. The FFO per security dropped 14.4% to 9.06 cents.

What else did it report?

Over the course of the first half of FY21, Abacus deployed $205 million of capital into the real estate sectors of office and self storage. This was done through both acquisitions and joint ventures, funded through a combination of debt and divestment of non-core assets.

Abacus said that it continues to reduce exposure to its non-core legacy investments, particularly in the residential land and mortgages sector.

The net tangible assets (NTA) per security of $3.26 reduced by 1.8% compared to FY20.

In terms of debt levels, Abacus said that its gearing reduced by 830 basis points to 18.2%.

Discussing the result, Abacus managing director Steven Sewell said:

Following an active half year including the entitlement offer, Abacus is in a position to extend its strong track record of investing into long term value enhancing assets. Realisation of non-core assets, together with the funds raised from the entitlement offer provides substantial acquisition capacity, ensuring Abacus will be in a strong position to continue to take advantage of opportunities in our key sectors of office and self storage.

Distribution

Due to the reduction of the funds from operations per security, the Abacus distribution declined by 10.1% to 8.5 cents per security.

This distribution represented a payout ratio of 94% of FFO.

Abacus outlook

The real estate investment trust (REIT) said that it remains a strong asset-backed, annuity-style Australian REIT. Given the prevailing market conditions, the board is expecting that the FY21 distribution will be paid with a payout ratio of between 85% to 95% of FFO.

Mr Sewell, the managing director, commented:

A combination of established and new collaborative joint ventures has created enduring investment opportunities and facilitated our debt recycling program. With 89% of total assets now deployed in office and self storage investments, the size, nature and market positioning of these key sector investments will permit the group to deliver recurring income and value creation over the long term.

More reading

• Top brokers name 3 ASX shares to sell today
• What’s going on with the MyFiziq (ASX:MYQ) share price today?
• Here’s why the Mach7 (ASX:M7T) share price is down 6% today
• Why the EML Payments (ASX:EML) share price is still pushing higher
• 2 of the best ETFs for ASX investors to buy today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Abacus Property (ASX:ABP) just revealed 85% profit growth in HY21 appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2NjdVE7

On Wednesday I looked at three ASX shares that brokers have given buy ratings to this week.

Unfortunately, not all shares are in favour with them right now. Three ASX shares that have just been given sell ratings by brokers are listed below. Here’s why these brokers are bearish on them:

Appen Ltd (ASX: APX)

According to a note out of Macquarie, its analysts have downgraded this artificial intelligence services company’s shares to an underperform rating and slashed the price target on them to $19.00. The broker is concerned that increased competition is leading to a structural loss of market share. It also fears that as competition intensifies, pricing could become a lever to differentiate between solutions. As a result, it suspects that there is downside risk to consensus estimates. The Appen share price is trading at $21.94 on Thursday.

Domino’s Pizza Enterprises Ltd (ASX: DMP)

Analysts at Credit Suisse have retained their underperform rating but lifted their price target on this pizza chain operator’s shares to $71.11. According to the note, the broker was impressed with Domino’s first half result and notes that its outlook was very positive. However, it believes this is being underpinned by COVID tailwinds, which will only be temporary. In light of this, it appears to believe that too much growth is being priced into its shares. The Domino’s share price is fetching $111.08 today.

Treasury Wine Estates Ltd (ASX: TWE)

A note out of Citi reveals that its analysts have retained their sell rating but lifted their price target on this wine company’s shares to $8.60 following its first half results. According to the note, while Treasury Wine posted a sizeable profit decline, it was better than it feared. Nevertheless, Citi believes the medium term will be difficult and suspects the market may be expecting too much from the company. Especially given the uncertainty around the reallocation of product meant for the China market. The Treasury Wine share price is trading at $11.82 on Thursday.

More reading

• Treasury Wine Estates (ASX:TWE) share price bubbles 12% higher
• ASX 200 up 0.2%: ANZ and CSL impress, Fortescue declares huge interim dividend
• Why CSL, Domino’s, IPH, & Treasury Wine shares are storming higher
• Leading broker tips Domino’s (ASX:DMP) share price to go even higher
• ASX 200 dips, EML soars after reporting, Appen sinks

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Appen Ltd. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool Australia has recommended Dominos Pizza Enterprises Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Top brokers name 3 ASX shares to sell today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3jZ3C3W

The MyFiziq Ltd (ASX: MYQ) share price hit a new 52-week high today. This follows the announcement of a binding agreement for integration and distribution in China.

Upon open, MyFiziq share’s rallied 12.7% to $2.04. However, the excitement appears to have worn off throughout the day. This is reflected in a flat share price at the time of writing, sitting at $1.81.

Details of the agreement

MyFiziq is a software application company that has developed a way of converting photos of the human body into 3D images. The images are then used within the company’s application to track weight, fitness, etc.

The deal struck today is with China-based Tinjoy Biotech Limited. Tinjoy owns multiple brands in China and services over 28 million monthly consumers. The company also owns 650 Dongchen pharmacies, catering to 3.5 million repeat monthly customers.

As part of the agreement, MyFiziq’s CompleteScan platform will be integrated and distributed by Tinjoy. This will be carried by integrating the platform with Tinjoy’s own WinScan Digital Health Platform (WinScan).

The WinScan platform itself addresses wellness, preventive health, and precision nutrition.

MyFiziq plans on utilising Tinjoy’s 500 person call centres to facilitate the China launch. However, as part of the deal, the company is expected to contribute US$100,000 towards the training of the call centre marketers. An additional US$100,000 will be made towards the marketing and launch of the product.

Reading the finer details

Included in the term sheet, revenue sharing between MyFiziq and Tinjoy will be a 70% and 30% split respectively. Furthermore, MyFiziq has the option to acquire up to 40% of the WinScan platform for a consideration of US$2 million to US$4 million. This option will remain valid for 12 to 24 months.

Depending on user sign-ups, MyFiziq might also be triggered to invest in Tinjoy based on the terms of the agreement.

The company anticipates collecting licensing fees from the commercial arrangement in the future, although no forecast could be given.

MyFiziq share price in view

The MyFiziq share price has performed exceptionally over the last 12 months, increasing by 598%. This blows the socks off the S&P/ASX 200 Index (ASX: XJO) loss of 3.4% over the same timeframe.

However, big returns typically come with big risk and at a market capitalisation of $232 million, MyFiziq is still a small fish.

More reading

• Why the MyFiziq (ASX:MYQ) share price is racing higher today

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What’s going on with the MyFiziq (ASX:MYQ) share price today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3jXgsjh

The Mach7 Technologies Ltd (ASX: M7T) share price has come under pressure on Thursday.

In afternoon trade, the enterprise imaging platform provider’s shares are down 6.5% to $1.42.

Despite this decline, the Mach7 share price is still up a massive 71% since this time last year.

Why is the Mach7 share price under pressure?

Investors have been selling Mach7 shares today following the release of its half year results.

For the six months ended 31 December, the company reported a 24% increase in sales to $10.9 million. Management notes that this was achieved despite some disruption caused by COVID-19.

Management advised that it has been pleased with the early success of the eUnity (Client Outlook) acquisition and its integration. It notes that it is seeing high demand for the enterprise viewing solution to enable teleradiology in a COVID environment.

Annualised recurring revenue (ARR) stood at $10.2 million at the end of the half. This is up 88% on the prior corresponding period and provides 64% coverage of operating expenses

In respect to earnings, Mach7 reported an operating loss of $1.2 million for the half. This was down from profit of $2.5 million a year earlier. However, this was due to the timing of revenue.

At the end of the period, the company was in a strong financial position with $14.4 million in cash and no debt.

Outlook

The second half has started strongly, with sales momentum accelerating. In fact, the company advised that it has already received $12 million of orders.

As a result, the company anticipates stronger revenue, positive operating earnings, and free cash flow in the second half of the year.

Mach7’s CEO, Mike Lampron, commented: “Following a challenging 2020 for new business opportunities I am pleased Mach7 remained focused on our customers and their enterprise imaging needs. The successful integration of eUnity viewing software into our platform is helping us to compete on larger opportunities. We’re excited about the momentum in our business and our differentiated enterprise imaging capabilities.”

More reading

• Why the Mach7 (ASX:M7T) share price is lifting today
• ASX 200 rises 0.4%
• Here’s why the Mach7 (ASX:M7T) share price just reached a multi-year high
• Why IDP Education, Lake Resources, Mach7, & Tyro shares are shooting higher
• Why the Mach7 (ASX:M7T) share price is surging 8% higher today

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends MACH7 FPO. The Motley Fool Australia has recommended MACH7 FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Mach7 (ASX:M7T) share price is down 6% today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2ZqS9kb